Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and a burning sensation in the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressants.
The Bullous Pemphigoid pipeline drugs market research report provides comprehensive information on the therapeutics under development for Bullous Pemphigoid, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects.
Bullous Pemphigoid Pipeline Drugs Market Segmentation by Targets
Some of the key targets of the Bullous Pemphigoid pipeline drugs market are Phosphodiesterase 4, C-C Chemokine Receptor Type 3, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C1s Subcomponent, Complement C5, Eotaxin, Granzyme B, and Heat Shock Protein 90 among others. Phosphodiesterase 4 leads this segment of the Bullous Pemphigoid pipeline drugs market.
Bullous Pemphigoid Pipeline Drugs Market Analysis, by Targets
For more Bullous Pemphigoid pipeline drugs market target insights, download a free report sample
Bullous Pemphigoid Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Bullous Pemphigoid pipeline drugs market are Phosphodiesterase 4 Inhibitor, C-C Chemokine Receptor Type 3 Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C1s Subcomponent Inhibitor, Complement C5 Inhibitor, and among others. Phosphodiesterase 4 Inhibitor leads the Bullous Pemphigoid pipeline drugs market in terms of MoA.
Bullous Pemphigoid Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Bullous Pemphigoid pipeline drugs market, download a free report sample
Bullous Pemphigoid Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Bullous Pemphigoid pipeline drugs market are intravenous, subcutaneous, oral, and topical. Intravenous leads the Bullous Pemphigoid pipeline drugs market in terms of RoA.
Bullous Pemphigoid Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Bullous Pemphigoid pipeline drugs market, download a free report sample
Bullous Pemphigoid Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Bullous Pemphigoid pipeline drugs market are small molecule, monoclonal antibody, fusion protein, protein, and recombinant protein. Small Molecule leads the Bullous Pemphigoid pipeline drugs market in terms of molecule types.
Bullous Pemphigoid Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Bullous Pemphigoid pipeline drugs market, download a free report sample
Bullous Pemphigoid Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Bullous Pemphigoid pipeline drugs market are Immungenetics AG, Akari Therapeutics Plc, Alkahest Inc, Alpine Immune Sciences Inc, Amgen Inc, Argenx SE, ARTham Therapeutics Inc, Innate Pharma SA, Kyowa Kirin Co Ltd, Regeneron Pharmaceuticals Inc, Regranion LLC, Sanofi, Satellos Bioscience Inc, SFA Therapeutics Inc, and viDA Therapeutics Inc among others. Immungenetics AG has the highest number of products under development.
Bullous Pemphigoid Pipeline Drugs Market Analysis, by Companies
To know more about the Bullous Pemphigoid pipeline drugs companies, download a free report sample
Bullous Pemphigoid Pipeline Drugs Market Report Overview
Key Targets | Phosphodiesterase 4, C-C Chemokine Receptor Type 3, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C1s Subcomponent, Complement C5, Eotaxin, Granzyme B, and Heat Shock Protein 90 among others |
Key Mechanisms of Action | Phosphodiesterase 4 Inhibitor, C-C Chemokine Receptor Type 3 Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C1s Subcomponent Inhibitor, Complement C5 Inhibitor, and among others |
Key Routes of Administration | Intravenous, Subcutaneous, Oral, and Topical |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Fusion Protein, Protein, and Recombinant Protein |
Key Companies | Immungenetics AG, Akari Therapeutics Plc, Alkahest Inc, Alpine Immune Sciences Inc, Amgen Inc, Argenx SE, ARTham Therapeutics Inc, Innate Pharma SA, Kyowa Kirin Co Ltd, Regeneron Pharmaceuticals Inc, Regranion LLC, Sanofi, Satellos Bioscience Inc, SFA Therapeutics Inc, and viDA Therapeutics Inc among others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid.
- The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bullous Pemphigoid therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bullous Pemphigoid therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Bullous Pemphigoid
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Bullous Pemphigoid pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Alkahest Inc
Alpine Immune Sciences Inc
Amgen Inc
Argenx SE
ARTham Therapeutics Inc
Immungenetics AG
Innate Pharma SA
Kyowa Kirin Co Ltd
Regeneron Pharmaceuticals Inc
Regranion LLC
Sanofi
Satellos Bioscience Inc
SFA Therapeutics Inc
viDA Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Bullous Pemphigoid pipeline drugs market?
Some of the targets of the Bullous Pemphigoid pipeline drugs market are Phosphodiesterase 4, C-C Chemokine Receptor Type 3, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C1s Subcomponent, Complement C5, Eotaxin, Granzyme B, and Heat Shock Protein 90 among others.
-
What are the key mechanisms of action in the Bullous Pemphigoid pipeline drugs market?
Some of the mechanisms of action of the Bullous Pemphigoid pipeline drugs market are Phosphodiesterase 4 Inhibitor, C-C Chemokine Receptor Type 3 Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C1s Subcomponent Inhibitor, Complement C5 Inhibitor, and among others.
-
What are the key routes of administration in the Bullous Pemphigoid pipeline drugs market?
The key routes of administration in the Bullous Pemphigoid pipeline drugs market are intravenous, subcutaneous, oral, and topical.
-
What are the key molecule types in the Bullous Pemphigoid pipeline drugs market?
The molecule types in the Bullous Pemphigoid pipeline drugs market are small molecule, monoclonal antibody, fusion protein, protein, and recombinant protein.
-
Which are the leading companies in the Bullous Pemphigoid pipeline drugs market?
Some of the leading companies in the Bullous Pemphigoid pipeline drugs market are Immungenetics AG, Akari Therapeutics Plc, Alkahest Inc, Alpine Immune Sciences Inc, Amgen Inc, Argenx SE, ARTham Therapeutics Inc, Innate Pharma SA, Kyowa Kirin Co Ltd, Regeneron Pharmaceuticals Inc, Regranion LLC, Sanofi, Satellos Bioscience Inc, SFA Therapeutics Inc, and viDA Therapeutics Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.